To include your compound in the COVID-19 Resource Center, submit it here.

Pfizer sues J&J over biosimilar competition

Pfizer Inc. (NYSE:PFE) filed a lawsuit alleging that Johnson & Johnson (NYSE:JNJ) violated antitrust laws by engaging in anticompetitive practices aiming at blocking sales of Pfizer’s biosimilar version of autoimmune drug Remicade infliximab.

Pfizer's antitrust

Read the full 356 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE